Comparison of WI-38 and NIH/3T3 Cells As Standards for the Evaluation of the Inhibition of Pancreatic Cancer Cell Lines by Organotin Polymers Derived From Drugs Without Aromaticity-Thiodiglycolic Acid, Chelidonic Acid, and Isomannide

摘要

We recently evaluated a number of different organotin polymers for their ability to inhibit two pancreatic cancer lines based on WI-38 and NIH/3T3 cell results. At times there is a difference in the ability to inhibit cell growth between materials that contain aromatic portions and those that lack these aromatic moieties. The present report describes results for polymers derived from three drugs that do not contain aromatic moieties within them. Pancreatic cancer afflicts close to 32,000 individuals each year in the United States and 168,000 worldwide, and nearly all patients die from the ravages of their disease within 3 to 6 months after detection. Treatment of pancreatic cancer is rarely successful as this disease typically metastasizes widely prior to detection. Organotin compounds have been known to inhibit cancer cell growth for over 80 years.1-3 More organotin compounds are available commercially than any other metal-containing organometallic.1-3 Further, more organotin compounds have undergone testing as potential anticancer agents than any other single group of compounds. We have synthesized a number of organotin-containing polymers with many of them exhibiting wide-spread inhibition of a number of cancer cell lines including those associated with lung, bone, colon, breast, ovarian, and prostate cancer and most recently, pancreatic cancer cell lines.2-43 These products generally exhibit good inhibition of cell growth equal to and greater than that found for cisplatin, one of the most widely employed chemotherapeutic drugs.